Summary
The results reported in the literature regarding glucagonaemia in genetically obese fa/fa rats are conflicting: normal, increased or decreased plasma glucagon levels have been reported. Due to the existence of several molecules endowed with glucagon-like immunoreactivity, it was thought that the conflicting data could be related to the degree of specificity of the different glucagon antibodies. Three antibodies that all qualified as being specific for pancreatic glucagon were used. It was found that, depending on the antibody, absolute values of basal glucagonaemia or arginine-induced glucagon output varied quantitatively and qualitatively in both lean and obese rats. When non-extracted basal or stimulated plasma samples were passed on a G-50 Sephadex column, glucagon-like immunoreactivity was present over a wide range of molecular weights, indicating the presence of non-pancreatic glucagon molecules. When an ethanol extraction was used, the fractions eluting from the G-50 Sephadex column contained only pancreatic glucagon immunoreactivity. It is concluded that ethanol extraction is necessary for the measurement of the 3500 daltons glucagon. Using this methodology it was found that: (1) basal glucagonaemia was low but identical in the two groups of rats; (2) arginine-induced glucagon secretion was greater in obese than in lean animals; (3) glucagonaemia was decreased by glucose administration in lean but not in obese rats. It is concluded that there are, in obese animals, dysfunctions of glucagon output that may play a role in their abnormal glucose tolerance.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rohner-Jeanrenaud F, Jeanrenaud B (1985) Involvement of the cholinergic system in insulin and glucagon oversecretion of genetic preobesity. Endocrinology 116: 830–834
Zucker LM, Antoniades HN (1972) Insulin and obesity in the Zucker genetically obese rat “fatty”. Endocrinology 90: 1320–1330
Assimacopoulos-Jeannet F, Jeanrenaud B (1976) The hormonal and metabolic basis of experimental obesity. Clin Endocrinol Metab 5: 337–365
Jeanrenaud B, Halimi S, van de Werve G (1985) Neuroendocrine disorders seen as triggers of the triad: obesity — insulin resistance — abnormal glucose tolerance. Diabetes Metab Rev 1: 261–291
Jeanrenaud B (1985) An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause. Diabetologia 28: 502–513
Eaton RP, Conway M, Schade DS (1976) Endogenous glucagon regulation in genetically hyperlipemic obese rats. Am J Physiol 230 (5): 1336–1341
Bryce GF, Johnson PR, Sullivan AC, Stern JS (1977) Insulin and glucagon: plasma levels and pancreatic release in the genetically obese Zucker rat. Horm Metab Res 9: 366–370
Hayek A, Woodside W (1979) Correlation between morphology and function in isolated islets of the Zucker rat. Diabetes 28: 565–569
Conlon JM (1980) The glucagon-like polypeptides-order out of chaos? Diabetologia 18: 85–88
Starke AAR, Erhardt G, Berger M, Zimmermann H (1984) Elevated pancreatic glucagon in obesity. Diabetes 33: 277–280
Heding LG (1971) Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 7: 10–19
Von Schenck H, Nilsson OR (1981) Radioimmunoassay of extracted glucagon compared with three non-extraction assays. Clin Chim Acta 109: 183–191
Rosselin G, Assan R, Yalow RS, Berson SA (1966) Separation of antibody bound and unbound peptide hormones labelled with iodine 131 by talcum powder and precipitated silica. Nature 212: 355–357
Wilson MA (1977) Radioimmunoassay of insulin. In: Abraham GE (ed) Handbook of radioimmunoassay. Dekker, New York Basel, pp 275–297
Von Schenck H (1983) Increased specificity of plasma glucagon radioimmunoassay by use of acetone extraction. Clin Chim Acta 127: 41–46
Assan R, Attali JR, Ballerio B, Boillot J, Girard JR (1977) Glucagon secretion induced by natural and artificial amino acids in the perfused rat pancreas. Diabetes 26: 300–307
Unger RH, Lefebvre PJ (1972) Glucagon physiology. In: Lefebvre PJ, Unger RH (eds) Glucagon: molecular physiology, clinical and therapeutic implications. Pergamon Press, Oxford New York Toronto Sydney Braunschweig, pp 213–244
Eaton RP, Oase R, Schade DS (1976) Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of therapy? Metabolism 25 (3): 245–249
Werner PL, Palmer JP (1978) Immunoreactive glucagon responses to oral glucose, insulin infusion and deprivation, and somatostatin in pancreatectomized man. Diabetes 27: 1005–1012
Nishikawa K, Ikeda H, Matsuo T (1981) Abnormal glucagon secretion in Zucker fatty rats. Horm Metab Res 13: 259–263
Mayer J, Andrus SB, Silides DJ (1953) Effect of diethyldithiocarbamate and other agents on mice with the obese-hyperglycemic syndrome. Endocrinology 53: 572–581
Flatt PR, Bailey CJ, Buchanan KD (1982) Regulation of plasma immunoreactive glucagon in obese hyperglycaemic (ob/ob) mice. J Endocrinol 95: 215–227
Bobbioni E, Coscelli C (1980) Portal levels of glucagon and insulin in VMH-lesioned rats. Horm Metab Res 12: 480–481
Goto Y, Carpenter RG, Berelowitz M, Frohman LA (1980) Effect of ventromedial hypothalamic lesions on the secretion of somatostatin, insulin, and glucagon by the perfused rat pancreas. Metabolism 29: 986–990
Rohner-Jeanrenaud F, Jeanrenaud B (1984) Oversecretion of glucagon by pancreases of ventromedial hypothalamic-lesioned rats: a re-evaluation of a controversial topic. Diabetologia 27: 535–539
Heding LG, Rasmussen SM (1972) Determination of pancreatic and gut glucagon-like immunoreactivity (GLI) in normal and diabetic subjects. Diabetologia 8: 408–411
Alford FP, Bloom SR, Nabarro JDN (1977) Glucagon levels in normal and diabetic subjects: use of a specific immunoabsorbent for glucagon radioimmunoassay. Diabetologia 13: 1–6
Borghi VC, Wajchenberg BL, Cesar FP (1984) Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Metabolism 33: 1068–1074
Reaven GM, Chen Y-DI, Golay A, Swislocki ALM, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 106–110
Unger RH (1978) Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27: 1691–1709
Ionescu E, Sauter JF, Jeanrenaud B (1985) Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol 248: E500-E506
Rohner-Jeanrenaud F, Proietto J, Ionescu E, Jeanrenaud B (1986) Mechanism of abnormal oral glucose tolerance of genetically obese (fa/fa) rats. Diabetes 35: 1350–1355
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rohner-Jeanrenaud, F., Jeanrenaud, B. Abnormal regulation of pancreatic glucagon secretion in obese fa/fa rats. Diabetologia 31, 235–240 (1988). https://doi.org/10.1007/BF00290591
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00290591